What is the 13F Pro Quality Score for ABT?

13F Pro ranks ABBOTT LABORATORIES (ABT) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View ABT's current score at https://13fpro.ai/research/ABT (free sign-up required for the full ranking).

Which hedge funds own the most ABT stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of ABT include BlackRock,, VANGUARD CAPITAL MANAGEMENT, STATE STREET. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/ABT as soon as new 13F filings post.

Where does 13F Pro source ABT data?

All ABBOTT LABORATORIES fundamentals and ownership data come directly from SEC EDGAR. ABBOTT LABORATORIES files with the SEC under CIK 1800. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is ABT in?

ABBOTT LABORATORIES (ABT) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is ABT research updated on 13F Pro?

ABT's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

ABBOTT LABORATORIES(ABT)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →NYSE

Institutional-grade research for retail investors

SEC EDGAR: CIK 1800 ABT stock profile & AI dashboard →

13F Pro Quality Score

67.0/100

Rank #491 of 2,879 stocksTOP 25%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

51.6/100

Profitability

73.1/100

Balance Sheet

77.6/100

Earnings Quality

45.5/100

Free Cash Flow

69.4/100

Institutional Flow

17.0/100

Revenue Scale

96.8/100

Dilution Risk

47.1/100

ABT Stock Analysis & AI Quality Score

AI stock analysis and institutional research for ABBOTT LABORATORIES (ABT), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ABT at 67.0/100 on a 32-signal composite quality model, placing it at rank #491 of 2,879 stocks — the top 25% of the AI-ranked universe. ABT scores in the top quartile across revenue scale (96.8), balance sheet strength (77.6). Areas of concern include institutional flow (17.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 47.1/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), ABBOTT LABORATORIES reports quarterly revenue of $11.2B, net income of $1.1B, an operating margin of 12.0%. Top institutional holders of ABT by reported 13-F value include BlackRock,, VANGUARD CAPITAL MANAGEMENT, STATE STREET, based on the most recent SEC filings. ABT trades on the NYSE exchange and files with the SEC under CIK 1800. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ABT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for ABBOTT LABORATORIES directly from SEC EDGAR. ABBOTT LABORATORIES's 13F Pro composite quality score has ranged between 44 and 79 since 2021, currently 67.0 — a stable long-term trajectory across 56 quarterly and live scoring snapshots.

✦

Fun facts about ABBOTT LABORATORIES

Quirks, history, and lore behind ABT — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. healthcare company · large-cap · listed on the NYSE · headquartered in northern Illinois.
2
The Numbers
Annual revenue around $20 billion, spread across four business segments including medical devices, diagnostics, nutrition, and branded generics.
3
The History
Founded in 1888 by a Chicago pharmacist, it spent over a century as a pharmaceutical giant before spinning off its pharma division as a separate company in 2013.
4
The Secret
That spinoff became one of the world's best-selling drug companies — but the parent kept the diagnostics and devices businesses and quietly became a pandemic testing powerhouse.
5
The Lore
Its rapid COVID-19 tests were everywhere in 2020–21, and its BinaxNOW card became as recognizable as a thermometer; it also makes the FreeStyle Libre glucose monitor beloved by diabetics worldwide.
6
The Giveaway
It spun off AbbVie (home of Humira), kept the diagnostics and nutrition arms — including Similac baby formula — and trades under a three-letter ticker that sounds like a London pub shorthand.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$11.2B

Net Income

Q1 2026

$1.1B

Free Cash Flow

Q1 2026

$916.0M

Operating Margin

Q1 2026

12.0%

D/E Ratio

Q1 2026

0.65

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+5.7% YoY

$44.33BFY 2025

FY22 $43.65BFY23 $40.11BFY24 $41.95BFY25 $44.33B

Net Income

-51.3% YoY

$6.52BFY 2025

FY22 $6.93BFY23 $5.72BFY24 $13.40BFY25 $6.52B

Operating Income

+18.0% YoY

$8.05BFY 2025

FY22 $8.36BFY23 $6.48BFY24 $6.83BFY25 $8.05B

EPS (Diluted)

-51.3% YoY

$3.72FY 2025

FY22 $3.91FY23 $3.26FY24 $7.64FY25 $3.72

Total Assets

+6.5% YoY

$86.71BFY 2025

FY22 $74.44BFY23 $73.21BFY24 $81.41BFY25 $86.71B

Total Debt

+2.2% YoY

$15.96BFY 2025

FY22 $19.02BFY23 $15.76BFY24 $15.63BFY25 $15.96B

Op. Cash Flow

+11.8% YoY

$9.57BFY 2025

FY22 $9.58BFY23 $7.26BFY24 $8.56BFY25 $9.57B

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$44.33B +5.7%	$41.95B +4.6%	$40.11B -8.1%	$43.65B +1.3%	$43.08B +24.5%	$34.61B
Net Income	$6.52B -51.3%	$13.40B +134.2%	$5.72B -17.5%	$6.93B -2.0%	$7.07B +57.3%	$4.50B
Operating Income	$8.05B +18.0%	$6.83B +5.4%	$6.48B -22.5%	$8.36B -0.7%	$8.43B +57.3%	$5.36B
EPS (Diluted)	$3.72 -51.3%	$7.64 +134.4%	$3.26 -16.6%	$3.91 -0.8%	$3.94 +57.6%	$2.50
Total Assets	$86.71B +6.5%	$81.41B +11.2%	$73.21B -1.6%	$74.44B -1.0%	$75.20B +3.6%	$72.55B
Total Debt	$15.96B +2.2%	$15.63B -0.9%	$15.76B -17.2%	$19.02B +1.2%	$18.80B +0.3%	$18.75B
Operating Cash Flow	$9.57B +11.8%	$8.56B +17.9%	$7.26B -24.2%	$9.58B -9.0%	$10.53B +33.3%	$7.90B

Get alerted when ABT's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for ABBOTT LABORATORIES including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of ABT

BlackRock, Inc.
$15.0B145,687,458 sh
VANGUARD CAPITAL MANAGEMENT LLC
$11.6B112,949,933 sh
STATE STREET CORP
$8.2B79,575,468 sh
Capital Research Global Investors
$5.1B49,775,362 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$4.9B47,944,891 sh
CHARLES SCHWAB INVESTMENT MANAGEMENT INC
$4.7B45,500,055 sh
GEODE CAPITAL MANAGEMENT, LLC
$4.0B39,148,795 sh
Capital International Investors
$3.8B37,498,227 sh
MORGAN STANLEY
$3.1B30,101,596 sh
WELLINGTON MANAGEMENT GROUP LLP
$2.8B27,070,518 sh

Fund	Value	Shares
BlackRock, Inc.	$15.0B	145,687,458
VANGUARD CAPITAL MANAGEMENT LLC	$11.6B	112,949,933
STATE STREET CORP	$8.2B	79,575,468
Capital Research Global Investors	$5.1B	49,775,362
VANGUARD PORTFOLIO MANAGEMENT LLC	$4.9B	47,944,891
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	$4.7B	45,500,055
GEODE CAPITAL MANAGEMENT, LLC	$4.0B	39,148,795
Capital International Investors	$3.8B	37,498,227
MORGAN STANLEY	$3.1B	30,101,596
WELLINGTON MANAGEMENT GROUP LLP	$2.8B	27,070,518

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put ABT on your watchlist

Track score changes the day ABBOTT LABORATORIES files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is ABT a good stock to buy?

13F Pro's AI-powered analysis of ABBOTT LABORATORIES (ABT) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ABT are available on the ABT stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own ABT?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ABT. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of ABBOTT LABORATORIES's investment landscape.